Verrica Pharmaceuticals Inc.(VRCA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,418 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in VRCA
Events flagged as statistical outliers against VRCA's own multi-year baseline — not fixed dollar thresholds.
- Insider cluster2026-08-18
4 insiders bought $210,890 of VRCA in 30 days — 8.0σ above this company's 2-year norm
View source filing →
VRCA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Verrica Pharmaceuticals Inc. (VRCA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores VRCA at 32.7/100 on a 32-signal composite quality model, placing it at rank #2,418 of 2,962 stocks — the bottom half of the AI-ranked universe. VRCA scores in the top quartile across revenue growth (94.7). Areas of concern include balance sheet strength (1.5) and revenue scale (5.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.0/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Verrica Pharmaceuticals Inc. reports quarterly revenue of $5.9M, net income of $-13.2M. Top institutional holders of VRCA by reported 13-F value include Caligan Partners, CANNELL CAPITAL, Affinity Asset Advisors, based on the most recent SEC filings. VRCA trades on the Nasdaq exchange and files with the SEC under CIK 1660334. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate VRCA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Verrica Pharmaceuticals Inc. directly from SEC EDGAR. Verrica Pharmaceuticals Inc.'s 13F Pro composite quality score has ranged between 23 and 33 since 2026, currently 32.7 — an improving long-term trajectory across 35 quarterly and live scoring snapshots.
Revenue
Q2 2026
$5.9M
Net Income
Q2 2026
$-13.2M
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+370.2% YoYNet Income
+76.6% YoYOperating Income
+81.5% YoYEPS (Diluted)
+88.6% YoYTotal Assets
-12.9% YoYTotal Debt
-100.0% YoYOp. Cash Flow
+71.1% YoYFree Cash Flow
+71.1% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $35.6M +370.2% | $7.6M +47.7% | $5.1M -43.3% | $9.0M -24.7% | $12.0M | — |
| Net Income | $-17.9M +76.6% | $-76.6M -14.3% | $-67.0M -173.6% | $-24.5M +30.2% | $-35.1M +17.8% | $-42.7M |
| Operating Income | $-12.2M +81.5% | $-65.9M -0.2% | $-65.8M -208.8% | $-21.3M +31.1% | $-30.9M +23.1% | $-40.2M |
| EPS (Diluted) | $-1.68 +88.6% | $-14.78 -898.6% | $-1.48 -105.6% | $-0.72 +44.6% | $-1.30 | — |
| Total Assets | $47.1M -12.9% | $54.1M -33.7% | $81.6M +82.5% | $44.7M -44.2% | $80.1M +8.1% | $74.2M |
| Total Debt | $0.00 -100.0% | $43.9M +2.4% | $42.9M | $0.00 -100.0% | $41.7M -41.0% | $70.6M |
| Operating Cash Flow | $-17.6M +71.1% | $-60.9M -57.9% | $-38.6M -106.8% | $-18.6M +32.4% | $-27.6M +8.7% | $-30.2M |
| Free Cash Flow | $-17.6M +71.1% | $-61.0M -56.5% | $-38.9M -105.5% | $-19.0M +33.4% | $-28.5M +10.1% | $-31.7M |
Get alerted when VRCA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Verrica Pharmaceuticals Inc. including:
Top Institutional Holders of VRCA
Caligan Partners LP
$5.7M923,910 shCANNELL CAPITAL LLC
$4.8M783,923 shAffinity Asset Advisors, LLC
$4.3M707,338 shVelan Capital Investment Management LP
$2.9M471,559 shARMISTICE CAPITAL, LLC
$2.6M426,304 shBOOTHBAY FUND MANAGEMENT, LLC
$1.7M280,734 shVANGUARD CAPITAL MANAGEMENT LLC
$1.7M279,310 shMariner, LLC
$1.3M207,230 shGEODE CAPITAL MANAGEMENT, LLC
$845.7K138,160 shBlackRock, Inc.
$455.0K74,344 sh
| Fund | Value | Shares |
|---|---|---|
| Caligan Partners LP | $5.7M | 923,910 |
| CANNELL CAPITAL LLC | $4.8M | 783,923 |
| Affinity Asset Advisors, LLC | $4.3M | 707,338 |
| Velan Capital Investment Management LP | $2.9M | 471,559 |
| ARMISTICE CAPITAL, LLC | $2.6M | 426,304 |
| BOOTHBAY FUND MANAGEMENT, LLC | $1.7M | 280,734 |
| VANGUARD CAPITAL MANAGEMENT LLC | $1.7M | 279,310 |
| Mariner, LLC | $1.3M | 207,230 |
| GEODE CAPITAL MANAGEMENT, LLC | $845.7K | 138,160 |
| BlackRock, Inc. | $455.0K | 74,344 |
Companies Similar to VRCA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
Ovid Therapeutics Inc.
TELA Bio, Inc.
MACROGENICS INC
Viridian Therapeutics, Inc.\DE
PRECISION BIOSCIENCES INC
AGIOS PHARMACEUTICALS, INC.
HERON THERAPEUTICS, INC. /DE/
BICYCLE THERAPEUTICS PLC
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put VRCA on your watchlist
Track score changes the day Verrica Pharmaceuticals Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is VRCA a good stock to buy?
13F Pro's AI-powered analysis of Verrica Pharmaceuticals Inc. (VRCA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for VRCA are available on the VRCA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. VRCA is classified as a small company.
Which hedge funds own VRCA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling VRCA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Verrica Pharmaceuticals Inc.'s investment landscape.